FDA approves the first pill meant to stop COVID-19 before it starts

The Food and Drug Administration approved ensitrelvir, sold as Xocova, on 29 May — more than two weeks ahead of its 16 June target decision date — for post-exposure prophylaxis of COVID-19 in people 12 and older [s2]. Shionogi's own announcement did not go out until 1 June, and the drug's label carries that same later date [s1]; the earlier date is FDA's own record of the approval action itself [s2]. It is the first oral drug approved in the United States for use before infection takes hold, aimed at someone who has been exposed to the virus but is not yet sick.

That distinction separates it from every other oral COVID-19 antiviral available so far. Paxlovid and similar treatments are prescribed after a positive test and the onset of symptoms, to shorten and reduce the severity of an infection already under way. Xocova is meant to be taken by someone who knows they were exposed — a household contact, for instance — with the goal of preventing symptomatic infection from developing at all.

What the approval covers

Xocova is a five-day oral regimen: three tablets (375 mg) on day one, then one tablet (125 mg) daily on days two through five [s1]. It is approved for people 12 years of age and older; safety and effectiveness have not been established in children under 12 [s1].

The approval rests on the SCORPIO-PEP trial, in which 2,041 household contacts of a person with confirmed COVID-19 were randomized to ensitrelvir (1,030 participants) or placebo (1,011 participants) [s1]. Shionogi describes it as the only Phase 3 trial of an oral antiviral to meet its primary endpoint for post-exposure prevention of COVID-19 [s1]. Ensitrelvir reduced the risk of developing symptomatic COVID-19 through day 10 by 67% relative to placebo [s1].

Adverse event rates were similar between arms — 15.1% among those taking ensitrelvir versus 15.5% on placebo — with headache, diarrhea and cough the most commonly reported side effects [s1]. Shionogi's announcement notes no reports of altered taste (dysgeusia), a side effect associated with some other antiviral options, among trial participants [s1].

Who should not take it, and why this matters for a prevention drug

Xocova carries contraindications with 14 specific medications, including rifampin, carbamazepine and phenytoin [s1] — the kind of interaction list that matters more for a prevention drug than a treatment drug, because prevention drugs are by definition offered to people who are not yet sick and may not be under a clinician's close watch at the moment of exposure. The label also states the drug may harm a developing fetus and requires effective contraception during treatment and for two weeks afterward, and that breastfeeding is not recommended during that same window [s1].

Frederick Hayden, Richardson Professor Emeritus of Clinical Virology at the University of Virginia, is quoted in Shionogi's release describing the drug's mechanism: "Ensitrelvir inhibits viral replication, helping protect people exposed to COVID-19 from developing illness" [s1]. Nathan McCutcheon, president and CEO of Shionogi Inc., called it "the first and only oral option clinically proven to help prevent symptomatic COVID-19 after exposure" [s1].

Why post-exposure prevention is a different category

A prevention drug changes the calculus of who might reasonably take it and when. Treatment drugs are prescribed to a person who is already confirmed positive — a bounded, identifiable population. A post-exposure prophylaxis drug is offered to people who test negative or have not yet tested, based on a known contact with someone who is positive, within a window before infection is established. That means broader potential use, a shorter decision window for prescribers and patients, and a genuine need for the interaction and pregnancy precautions to be communicated clearly at the point of exposure rather than after diagnosis — a logistical difference the approval itself does not resolve.

What is not yet known

Shionogi's announcement does not specify a list price or state how quickly the drug will be available at retail pharmacies, nor does it address insurance coverage. It also does not describe what guidance, if any, the CDC or professional societies plan to issue about who should be prioritized for post-exposure use — household contacts generally, or specific higher-risk groups, such as older adults or people who are immunocompromised.

The trial population was defined as household contacts of a confirmed case, a group with unusually clear and immediate awareness of exposure. Whether the same approach translates to less-defined exposure scenarios — a shared workplace, a large gathering — is a real-world use question the approval itself does not answer.

What to watch

Whether CDC or professional bodies issue prioritization guidance for who should receive post-exposure ensitrelvir. Pricing and coverage decisions once the drug reaches pharmacies. And whether real-world use patterns match the household-contact population the trial was built around, or whether prescribing expands into broader or less clearly defined exposure situations than the evidence currently covers.

This article is informational and is not medical advice. Decisions about taking any antiviral medication, including after a known exposure, belong with a clinician familiar with an individual's health history and current medications.

Sources

• [s1] Shionogi Inc., "Shionogi Announces FDA Approval of XOCOVA (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure," 1 June 2026. https://www.shionogi.com/us/en/news/2026/06/shionogi-announces-fda-approval-of-xocova-ensitrelvir-the-first-and-only-oral-option-to-help-prevent-covid-19-following-exposure.html